Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects
Bioorganic Chemistry · 2026-09 · 180 · 110212
DOI: 10.1016/j.bioorg.2026.110212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Kequan Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China; Schoo…. Hauptthemen laut MEDLINE: Receptors, sigma, Hyperalgesia, Analgesics, Spiro Compounds. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hyperalgesia is a common clinical condition that can be alleviated by blocking the sigma-1 receptor (σ1R). This study focuses on designing a series of 2,8-diazaspiro[4.5]decan-3-one scaffold compounds derived from 4-IBP, with the aim of developing novel σ1R-selective analgesic antagonists. Using radioligand binding assays, we evaluated the affinity (Ki values) of the designed compounds. Compound 52 emerged as a high-affinity, with a Ki of 8.6 nM for σ1R. Pharmacokinetic evaluation showed that compound 52 has a half-life of 2.79 h, and at the 1 h-point, the brain-to-plasma total drug ratio was 4.04. Analgesic efficacy, assessed through Von Frey and Hargreaves tests, demonstrated significant pain relief against both mechanical and thermal stimuli at a dose of 30 mg/kg, with effects comparable to those of E-52862. Our study indicates that compound 52 is a promising candidate for the treatment of hyperalgesia, exhibiting strong selectivity and efficacy as a σ1R antagonist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China; School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 22…
- School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China.
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.. Electronic address:…
- School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China; State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 2012…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fu, K., Pan, R., Hu, S., Liu, J., Zhao, H., Xu, W., Yang, R., Chen, D., Guo, D., & Xiong, B. (2026). Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects. Bioorganic Chemistry, 180, 110212. https://doi.org/10.1016/j.bioorg.2026.110212
Vancouver
Fu K, Pan R, Hu S, Liu J, Zhao H, Xu W, et al. Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects. Bioorganic Chemistry. 2026;180:110212. doi:10.1016/j.bioorg.2026.110212
BibTeX
@article{Fu2026,
author = {Fu, Kequan and Pan, Rongrong and Hu, Shujuan and Liu, Jiajing and Zhao, Huimin and Xu, Wen and Yang, Ruicong and Chen, Danqi and Guo, Dong and Xiong, Bing},
title = {Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {180},
pages = {110212},
doi = {10.1016/j.bioorg.2026.110212}
}
EUVIMED